Podcasts about Neurotherapeutics

UC Davis researchers recently announced the development of a new neuroplasticity-promoting drug closely related to LSD that harnesses the psychedelic's therapeutic power with reduced hallucinogenic potential.KVMR's Sherrie Cunningham spoke to Dr. David E. Olson, director of the Institute for Psychedelics and Neurotherapeutics at UC Davis to learn more. 

How researchers are creating non-hallucinogenic psychedelics Guest: Dr. David Olson, Professor in the Department of Biochemistry and Molecular Medicine at UC Davis, Director of the UC Davis Institute for Psychedelics and Neurotherapeutics, and Co-founder and Chief Innovation Officer at Delix Therapeutics Learn more about your ad choices. Visit megaphone.fm/adchoices

Have scientists discovered evidence of string theory? Guest: Michael Kavic, Professor of Chemistry and Physics at the State University of New York at Old Westbury and Co-Author of the Study Weekly Cecchini Check-In for Apr 11, 2025 Guest: Reggie Cecchini, Washington Correspondent for Global News How researchers are creating non-hallucinogenic psychedelics Guest: Dr. David Olson, Professor in the Department of Biochemistry and Molecular Medicine at UC Davis, Director of the UC Davis Institute for Psychedelics and Neurotherapeutics, and Co-founder and Chief Innovation Officer at Delix Therapeutics Why is BC urging the government to scrap US contracts? Guest: Ravi Kahlon, Minister of Housing and Municipal Affairs, and Chair of BC's Tariff Response Committee Kickin It with the Caps for Apr 11, 2025 Guest: Jesper Sørensen, Head Coach of the Vancouver Whitecaps Who should be the MP for Richmond East—Steveston? Guest: Parm Bains, Liberal Candidate for Richmond East—Steveston Guest: Keefer Pelech, NDP Candidate for Richmond East—Steveston Guest: Zach Segal, Conservative Candidate for Richmond East—Steveston Learn more about your ad choices. Visit megaphone.fm/adchoices

When I learned ACT (Acceptance and Commitment Therapy), it changed my OT practice and it changed how I navigate my own life. This is why I have created so many things that include ACT concepts - the ACTivate Vitality coaching program for OT business owners who want to thrive without the hustle, the ACTivate Vitality Personal Development Planner, and the Practical ACT for OTs course... that last one has a Black Friday promo coming out later this week. This podcast is taken from a presentation I did recently in a Facebook group for mental health OTs called MHOT ~ A Collective. It's a helpful introduction to using ACT as a modality in your OT practice to facilitate occupational engagement, particularly when clients are stuck in patterns of avoidance of difficult thoughts, feelings, or sensations. ✴️✴️Head to the Practical ACT for OTs course website to sign up to be notified when the Black Friday early bird registration and promo opens up or when the course officially starts toward the end of January, 2025.✴️✴️   Here are some resources mentioned in this episode: Balance Works OT - Carlyn's OT practice  Balance Works - Carlyn's personal and professional develoment services   ACTivate Vitality Program and Mastermind for OTs who want to THRIVE without the HUSTLE ACTivate Vitality Personal Development Planner  Practical ACT for OTs Clinical Education Vitality Guide - free download with ACT starter resources ACT Made Simple Facebook Group Choice Point - Russ Harris MHOT ~ A Collective Facebook Group   Article Cited: Dindo L, Van Liew JR, Arch JJ. Acceptance and Commitment Therapy: A Transdiagnostic Behavioral Intervention for Mental Health and Medical Conditions. Neurotherapeutics. 2017 Jul;14(3):546-553. doi: 10.1007/s13311-017-0521-3. PMID: 28271287; PMCID: PMC5509623.     Shoutout to our sponsor, Jane, the all-in-one practice management software we love. To see how Jane can help you reclaim your evenings and weekends, head over and meet Jane to book a personalized demo and, if you're ready to get started, you can use the code VITALITY at the time of sign-up for a 1-month grace period applied to your new account.

Professor James Jackson PsyD is a licensed neuropsychologist and internationally renowned expert on Long Covid and its effects on cognitive and mental health functioning. He is a research professor of Medicine and Psychiatry at Vanderbilt, University School of Medicine Consortium in Nashville, Tennessee in the USA. He is interviewed by Dr Funmi Okunola about the psychological management of mental illness in Long COVID.References1. “Clearing the Fog from Surviving to Thriving with Long COVID – A Practical Guide”.2. The Long COVID Handbook by Gez Medinger & Professor Danny Altmann3.Dindo L, Van Liew JR, Arch JJ. Acceptance and commitment therapy: a transdiagnostic behavioral intervention for mental health and medical conditions. Neurotherapeutics. 2017 Jul 1;14(3):546-53.4.REVERSE LC - Randomized trial Evaluating Baricitinib on pERSistent nEurologic and Cardiopulmonary Symptoms of Long COVID5."Live Like You Were Dying" - lyrics6.Field Of Dreams -Movie7.GAD-78.The Hospital Anxiety & Depression Scale9.The Impact of Events Scale Revised10.Post Traumatic Stress Disorder Checklist

In today's episode I welcome back Dr. Michelle Leary, a functional medicine physician and the director of Functional Medicine at Vida Integrated Health.Many of us in middle age have parents who are struggling with dementia and/or Alzheimer's, and today I'm talking with Dr. Leary about longevity medicine and brain health, for women in particular. In this episode you're going to learn all about what longevity medicine is, and what you can do to improve your quality of life and protect your brain & cognitive health as you age.Dr. Leary talks about the impact of genetics, particularly the APOE gene, on Alzheimer's disease risk and how to test for it. Thankfully, genetics don't necessarily dictate our fate, and Dr. Leary shares how you can promote longevity and minimize your risk of degenerative brain disease by leveraging sleep, nutrition, metabolic health, and exercise. She also discusses the role of chronic stress, insulin resistance and hormones, particularly estrogen, in brain health and cognitive decline. Where to find Dr. Leary:Powersexbeauty.comThinkvida.comMentioned in the episode:Dale Bredesen – The End of AlzheimersDr. Bredesen's Program PreCode and ReCode ProgramsReferences:Russell JK, Jones CK, Newhouse PA. The Role of Estrogen in Brain and Cognitive Aging. Neurotherapeutics. 2019 Jul;16(3):649-665. doi: 10.1007/s13311-019-00766-9. PMID: 31364065; PMCID: PMC6694379.Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: Triad of risk of Alzheimer's disease. J Steroid Biochem Mol Biol. 2016 Jun;160:134-47. doi: 10.1016/j.jsbmb.2016.03.012. Epub 2016 Mar 8. PMID: 26969397; PMCID: PMC4905558.Scheyer O, Rahman A, Hristov H, Berkowitz C, Isaacson RS, Diaz Brinton R, Mosconi L. Female Sex and Alzheimer's Risk: The Menopause Connection. J Prev Alzheimers Dis. 2018;5(4):225-230. doi: 10.14283/jpad.2018.34. PMID: 30298180; PMCID: PMC6198681.Islam MT. Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res. 2017 Jan;39(1):73-82. doi: 10.1080/01616412.2016.1251711. Epub 2016 Nov 3. PMID: 27809706.Sadeghmousavi S, Eskian M, Rahmani F, Rezaei N. The effect of insomnia on development of Alzheimer's disease. J Neuroinflammation. 2020 Oct 6;17(1):289. doi: 10.1186/s12974-020-01960-9. PMID: 33023629; PMCID: PMC7542374.Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M. Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer's Disease. J Alzheimers Dis. 2018;64(4):1077-1083. doi: 10.3233/JAD-180141. PMID: 30010124; PMCID: PMC6226313. Daniel JM, Lindsey SH, Mostany R, Schrader LA, Zsombok A. Cardiometabolic health, menopausal estrogen therapy and the brain: How effects of estrogens diverge in healthy and...

The United States is facing a real mental health crisis. In the last few years, one possible treatment has gotten a lot of press: psychedelic drugs. But what is actually happening in a person's brain when they take a psychedelic? Could understanding the biology and the chemistry allow us to make better and safer versions of these drugs—and maybe even create psychedelics without the hallucinations?In this episode, we speak with Assoc. Prof. David E. Olson, founding director of the UC Davis Institute of Psychedelics and Neurotherapeutics. Olson and his lab have been researching the therapeutic effects of psychedelic drugs and how they could be used to treat neuropsychiatric diseases, including depression, anxiety disorders and even addiction. His lab's is researching how to develop non-hallucinogenic psychedelics, also called next-generation neurotherapeutics.

Gliederung was ist ADHS? (mit Fallbeispiel) Konsequenzen für die Partnerschaft Tipps für eure Beziehung Studien und Quellen zum Thema: 1) Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012 Jul;9(3):490-9. doi: 10.1007/s13311-012-0135-8. • 2) Ayano G, Yohannes K, Abraha M. Epidemiology of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in Africa: a systematic review and meta-analysis. Ann Gen Psychiatry. 2020 Mar 13;19:21. doi: 10.1186/s12991-020-00271-w. • 3) European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010 Sep 3;10:67. doi: 10.1186/1471-244X-10-67. • 4) Wilens TE, Morrison NR. The intersection of attention-deficit/hyperactivity disorder and substance abuse. Curr Opin Psychiatry. 2011 Jul;24(4):280-5. doi: 10.1097/YCO.0b013e328345c956. • 5) Balazs J, Kereszteny A. Attention-deficit/hyperactivity disorder and suicide: A systematic review. World J Psychiatry. 2017 Mar 22;7(1):44-59. doi: 10.5498/wjp.v7.i1.44. • 6) Coleman WL. Social competence and friendship formation in adolescents with attention-deficit/hyperactivity disorder. Adolesc Med State Art Rev. 2008 Aug;19(2):278-99, • 7) ADHD in Adults: What the Science Says byRussell A. Barkley, Kevin R. Murphy and Mariellen Fischer, The Guilford Press, 2008, pp. 380-384. • 8) The ADHD Effect on Marriage, Melissa Orlov • 9) Barkley, R. A. (2017). When an adult you love has ADHD: Professional advice for parents, partners, and siblings. American Psychological Association. https://doi.org/10.1037/15963-000Wenn du mich und den Podcast unterstützen möchtest, dann bewerte den Podcast gerne und schicke ihn an jemanden weiter, der sich auch dafür interessieren würde.  Jede Woche neue Tipps, Übungen und Hintergrundinformationen aus meiner paartherapeutischen Praxis. Melde dich hier für den Newsletter an.  Du hast Feedback oder Fragen? Dann schreib mir auf Instagram. Du möchtest eine persönliche (Online)Beratung oder Paartherapie mit mir? Dann schreib mir eine Mail an: kontakt@paartherapiebonn.com. Mehr zu mir und meiner Arbeit findest du ⁠hier⁠. Disclaimer: Es handelt sich bei dem Fallbeispiel, um ein fiktives Beispiel und nicht um eine echte Person. Die Inhalte ergeben sich aus verschiedenen Geschichten und KlientInnen, die ich in einem Beispiel zusammengefasst habe.  --- Send in a voice message: https://podcasters.spotify.com/pod/show/anouk-algermissen/message

MedRhythms is a groundbreaking digital therapeutics company that built the world's first prescription music product. This pioneering product uses the neurological capacities of music to improve walking, mobility, and related functional outcomes, especially for those with multiple sclerosis, Parkinson's, and stroke effects. Learn how it is prescribed and administered, and the science behind music's contribution to the product's effectiveness. Links and notes related to this episode can be found at https://mpetersonmusic.com/podcast/episode169 Connect with us: Newsletter: https://mpetersonmusic.com/subscribe Facebook: https://www.facebook.com/EnhanceLifeMusic/ Instagram: https://www.instagram.com/enhancelifemusic/ LinkedIn: https://www.linkedin.com/in/mpetersonpiano/ Twitter: https://twitter.com/musicenhances Sponsorship information: https://mpetersonmusic.com/podcast/sponsor Leave us a review on Podchaser.com! https://www.podchaser.com/podcasts/enhance-life-with-music-909096 In-episode promo:  The Business Side of Music podcast https://www.businesssideofmusic.com  JAMBAR https://jambar.com/ 

Interview with Dr. Brent Nelson regarding how his experiences in both the computer software and finance industries inspired his career in neurology and led to his passion in treating complex neurological disorders including Major Depressive Disorder. Dr. Nelson was born and raised in the Twin Cities. He attended the University of St. Thomas in Saint Paul, receiving a Bachelor's degree in Biology with a research focus in neuroscience and brain stimulation. During and post-college, he spent 9 years doing software development in manufacturing and the financial services industry. In 2006, he decided to go back to school and subsequently completed a medical degree at the University of Minnesota in 2011. He then completed a general psychiatry residency there along with a clinical research fellowship in neuromodulation. After graduation, he spent a year as a fulltime faculty member and as Executive Director of the transcranial magnetic stimulation program at the University of Minnesota and the Minneapolis VA Medical Center. His clinical focus was on treatment-resistant depression and mental health management in epilepsy and other complex neurological disorders. His research focused on non-surgical brain stimulation in depression, brain injury, and schizophrenia.Dr. Nelson serves as the Chief Medical Information Officer and is a consultant for the Center for Neurotherapeutics at PrairieCare, which is focused on ground-breaking technologies used in the treatment of complex disorders such as Major Depressive Disorder.PrairieCare, a division of Newport Healthcare, is one of the nation's most innovative psychiatric health systems, offering psychiatric services for all ages, including free mental health assessments, clinic services, intensive outpatient programs (IOP), partial hospital programs (PHP) and residential services. In his free time, Dr. Nelson enjoys software development, IoT maker projects, 3D design, and woodworking. He is also very active in advocacy and trying to improve access to novel therapies for those on public and low-income medical plans.Well Connected Twin Cities is connecting you with local health and wellness professionals in your community. Discover what's possible by surfing the directory, taking a class, or attending the next event. http://wellconnectedtwincities.com/Follow us on instagram https://instagram.com/wellconnectedtwincities

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: February 6, 2020 The sole FDA-approved indication for clobazam is as a therapeutic adjunct in Lennox-Gastaut syndrome. But as more and more clinicians publish their experience with the off-label success of certain therapies, we may see new indications for this and other pharmacologic agents in the treatment of neurologic disease. Produced by James E Siegler. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. Music courtesy of Chris Zabriskie, Milton Arias, and John Bartmann. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Bresnahan R, Martin-McGill KJ, Williamson J, Michael BD, Marson AG. Clobazam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev 2019;10(10):CD004154. PMID 31638272 Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990;17(3):317-9. PMID 2207888 Mahmoud SH, Rans C. Systematic review of clobazam use in patients with status epilepticus. Epilepsia Open 2018;3(3):323-330. PMID 30187002 Montenegro MA, Arif H, Nahm EA, Resor SR Jr, Hirsch LJ. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center. Clin Neuropharmacol 2008;31(6):333-8. PMID 19050410 Montenegro MA, Cendes F, Noronha AL, et al. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 2001;42(4):539-42. PMID 11440350 Ng YT, Collins SD. Clobazam. Neurotherapeutics 2007;4(1):138-44. PMID 17199029 Remy C. Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia 1994;35 Suppl 5:S88-91. PMID 8039479 Schmidt D, Rohde M, Wolf P, Roeder-Wanner U. Clobazam for refractory focal epilepsy. A controlled trial. Arch Neurol 1986;43(8):824-6. PMID: 3089202. PMID 3089202 YOUTUBE EXCERPTS (shared via fair use)  Kathryn Davis MD (Hospital of the University of Pennsylvania): https://www.youtube.com/watch?v=XInZ7...  Patty McGoldrick NP MPA (Beth Israel Deaconness Medical Center/Roosevelt Hospital): https://www.youtube.com/watch?v=sE2Bk...  We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Dr. Porter is the Director of Dementia, Alzheimer's disease, and Neurocognitive Disorders at the Pacific Brain Health Center at Pacific Neuroscience Institute (PNI) located at Providence Saint John's Health Center in Santa Monica, CA. In addition, she is a Professor of Neurosciences, Department of Translational Neurosciences and Neurotherapeutics at John Wayne Cancer Institute.https://www.pacificneuroscienceinstitute.org/about-us/our-team/ | (310) 582-7640

This episode is dedicated to clarification of a podcast between Joe Rogan and Max Lugavere, two popular influencers that have a large audience. They discussed Alzheimer's disease and brain health in general and some of the information that was shared was not accurate, which can be really harmful. This is by no means an attack on Rogan or Lugavere. After listening to the conversation, we think Lugavere may not be quite familiar with the data regarding brain health, and it would be important to set the record straight and share the evidence with people and let them decide what's best for them. Having seen thousands of patients with dementia, whether it's Alzheimer's disease, frontotemporal lobe dementia, Lewy Body Dementia and others, we feel it's our responsibility to share evidence based data as opposed to feel-good, self confirming anecdotes. Relevant references: Ketogenic Diet: Phillips, M. C et al. (2021). Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease. Alzheimer's research & therapy, 13(1), 1-12. Lilamand, M et al. (2022). Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review. Frontiers in Nutrition, 1324. Włodarek, D. (2021). Food for thought: the emerging role of a ketogenic diet in Alzheimer's disease management. Expert Review of Neurotherapeutics, 21(7), 727-730. Cronjé, H et al. (2021). Ketogenic therapies in mild cognitive impairment and dementia. Current Opinion in Lipidology, 32(5), 330-332. LDL Cholesterol metabolism and risk of Alzheimer's: Andrews, S et al., collaborators of the Alzheimer's Disease Genetics Consortium. (2021). Causal associations between modifiable risk factors and the Alzheimer's phenome. Annals of neurology, 89(1), 54-65. Olmastroni, E et al. (2022). Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. European Journal of Preventive Cardiology, 29(5), 804-814. Iwagami, M et al. (2021). Blood cholesterol and risk of dementia in more than 1· 8 million people over two decades: a retrospective cohort study. The Lancet Healthy Longevity, 2(8), e498-e506. Tan, Z. S et al. (2003). Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Archives of Internal Medicine, 163(9), 1053-1057. Kivipelto, M et al. (2002). Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Annals of internal medicine, 137(3), 149-155. Zhou, Z et al. (2020). Low-density lipoprotein cholesterol and Alzheimer's disease: a systematic review and meta-analysis. Frontiers in aging neuroscience, 12, 5. Sáiz-Vazquez, O et al. (2020). Cholesterol and Alzheimer's disease risk: a meta-meta-analysis. Brain sciences, 10(6), 386. Wingo, A. P et al. (2022). LDL cholesterol is associated with higher AD neuropathology burden independent of APOE. Journal of Neurology, Neurosurgery & Psychiatry, 93(9), 930-938. The Nigerian Paradox Study: Hall, K et al. (2006). Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology, 66(2), 223-227. Vascular health and Alzheimer's disease: Levit, A et al. (2020). Neurovascular unit dysregulation, white matter disease, and executive dysfunction: the shared triad of vascular cognitive impairment and Alzheimer disease. Geroscience, 42(2), 445-465. The Effect of Lifestyle on Alzheimer's Risk: Dhana, K et al. (2020). Healthy lifestyle and the risk of Alzheimer dementia: Findings from 2 longitudinal studies. Neurology, 95(4), e374-e383.  Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines. Geneva, Switzerland: World Health Organization; 2019.  https://apps.who.int/iris/bitstream/handle/10665/312180/9789241550543-eng.pdf. Accessed December 4, 2019. MIND Diet: Morris, M. C et al. (2015). MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimer's & Dementia, 11(9), 1007-1014. Morris, M. C et al. (2015). MIND diet slows cognitive decline with aging. Alzheimer's & dementia, 11(9), 1015-1022. van den Brink, A. C et al. (2019). The Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets are associated with less cognitive decline and a lower risk of Alzheimer's disease—a review. Advances in Nutrition, 10(6), 1040-1065. Kheirouri, S., & Alizadeh, M. (2021). MIND diet and cognitive performance in older adults: a systematic review. Critical Reviews in Food Science and Nutrition, 1-19. Hosking, D. E et al. (2019). MIND not Mediterranean diet related to 12-year incidence of cognitive impairment in an Australian longitudinal cohort study. Alzheimer's & Dementia, 15(4), 581-589. Melo van Lent, D et al. (2021). Mind diet adherence and cognitive performance in the Framingham heart study. Journal of Alzheimer's Disease, 82(2), 827-839. Dhana, K et al. (2021). MIND diet, common brain pathologies, and cognition in community-dwelling older adults. Journal of Alzheimer's Disease, 83(2), 683-692. Thomas, A et al. (2022). Association of a MIND Diet with Brain Structure and Dementia in a French Population. The Journal of Prevention of Alzheimer's Disease, 1-10. Arjmand, G et al. (2022). Effect of MIND diet intervention on cognitive performance and brain structure in healthy obese women: a randomized controlled trial. Scientific Reports, 12(1), 1-14. Nutrition and Dementia Prevention: Yassine, H. N et al. (2022). Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group. The Lancet Healthy Longevity, 3(7), e501-e512. Scarmeas, N et al. (2018). Nutrition and prevention of cognitive impairment. The Lancet Neurology, 17(11), 1006-1015.   Publications by Lugavere's mentor, Dr. Richard Isaacson: Isaacson, R. S et al. (2019). Individualized clinical management of patients at risk for Alzheimer's dementia. Alzheimer's & Dementia, 15(12), 1588-1602. Amini, Y., Saif, N., Greer, C., Hristov, H., & Isaacson, R. (2020). The role of nutrition in individualized Alzheimer's risk reduction. Current nutrition reports, 9(2), 55-63.  Isaacson, R. S. (2019). Advances in early diagnosis and treatment strategies in the management of Alzheimer's disease. Journal of Managed Care Medicine, 22(4), 17-21. Berkowitz, C. L., Mosconi, L., Rahman, A., Scheyer, O., Hristov, H., & Isaacson, R. S. (2018). Clinical application of APOE in Alzheimer's prevention: a precision medicine approach. The journal of prevention of Alzheimer's disease, 5(4), 245-252. BOOK: The Alzheimer's Prevention & Treatment Diet: Using Nutrition to Combat the Effects of Alzheimer's Disease. Isaacson, R. S., & Ochner, C. N. (2016). Square One Publishers, Inc. Podcast episodes mentioned: The Proof with Simon Hill: The carnivore diet, veganism and nutrition misinformation | Dr Alan Flanagan.  The Proof with Simon Hill: Debate: Seed Oils And Heart Disease | Tucker Goodrich And Dr Matthew Nagra   Our publications relevant to this topic: Sherzai, A., Edland, S. D., Masliah, E., Hansen, L., Pizzo, D. P., Sherzai, A., & Corey-Bloom, J. (2013). Spongiform change in dementia with Lewy bodies and Alzheimer disease. Alzheimer Disease & Associated Disorders, 27(2), 157-161. Whitehair, D. C., Sherzai, A., Emond, J., Raman, R., Aisen, P. S., Petersen, R. C., & Fleisher, A. S. (2010). Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimer's & Dementia, 6(5), 412-419. Lazar, E., Sherzai, A., Adeghate, J., & Sherzai, D. (2021). Gut dysbiosis, insulin resistance and Alzheimer's disease: review of a novel approach to neurodegeneration. Frontiers in Bioscience-Scholar, 13(1), 17-29. Sherzai, D., & Sherzai, A. (2019). Preventing Alzheimer's: Our most urgent health care priority. American journal of lifestyle medicine, 13(5), 451-461. Sherzai, A. Z., Sherzai, A. N., & Sherzai, D. (2022). A Systematic Review of Omega-3 Consumption and Neuroprotective Cognitive Outcomes. American Journal of Lifestyle Medicine, 15598276221117102. Sherzai, D., Sherzai, A., & Sherzai, A. (2022). Lifestyle Intervention and Alzheimer Disease. The Journal of Family Practice, 71(1 Suppl Lifestyle), eS83-eS89. Sherzai, D., Sherzai, A., Lui, K., Pan, D., Chiou, D., Bazargan, M., & Shaheen, M. (2016). The association between diabetes and dementia among elderly individuals: a nationwide inpatient sample analysis. Journal of Geriatric Psychiatry and Neurology, 29(3), 120-125. Sherzai, A., Sherzai, D., Pilot, M., & Ovbiagele, B. (2016). Prevalence of the Diagnoses of Alzheimer's Dementia, Non-Alzheimer's Dementia and Vascular Dementia Among Hospitalized Stroke Patients: A National Inpatient Sample Analysis, 1999-2012 (P1. 125).   Follow us on social media: Instagram: The Brain Docs @thebraindocs Facebook: The Brain Docs Website: TheBrainDocs.com

Naveed Ejaz is VP Product Strategy and Clinical Development (formerly Director of Digital Therapies) at MindMaze, the very first unicorn from Switzerland, pioneering the fascinating field of digital neurotherapeutics. Underneath these fluffy terms lies the concept of “software-as-a-medicine”, where pieces of code come together to drive a behavioural intervention, enabling patients suffering from neurological diseases to improve their condition. In the area of neurology where pharmaceutical and medical device solutions have been limited, this field opens up promising perspectives in terms of extended care delivery, stronger engagement from patients towards their treatment plans, and facilitated care coordination. We talked with Naveed about how video games could be leveraged to create an engaging therapy for the benefits of patients suffering from neurological diseases, the challenges that companies involved in the field of digital therapeutics face, MindMaze's vision to build an integrated platform delivering cutting-edge rehabilitation programs for patients, and why all of that is not purely about technology but rather engaging the patients as much as all healthcare professionals surrounding them. We also get a sneak peek at the activities led within MindMaze Labs, the R&D division of the company partnering with institutions like Formula One to understand better how the brain works under extreme situations! Timeline: 04:43 - Naveed's background and what drove him towards neuroscience and neurorehabilitation 13:03 - What digital neurotherapeutics are and what “software-as-a-medicine” entails 20:30 - Conceptual acceptability towards digital neurotherapeutics in healthcare 23:38 - The benefits of gamification in neurorehabilitation therapies 29:44 - How the rehabilitation therapies from MindMaze are designed 42:57 - The key characteristics of a therapeutic video game that keeps patients engaged 47:15 - Rehabilitating fine dextrous motion versus gross movement 52:04 - Naveed's role as VP Product Strategy and Clinical Development (formerly Director of Digital Therapies) 55:03 - Initiatives led by MindMaze Labs R&D center and partnering with Formula One What we also talked about with Naveed: BrainGate John Krakauer Johns Hopkins University MindMaze Labs Formula One If you want to know more about MindMaze, we invite you to consult their website and follow their activities on LinkedIn. As mentioned by Naveed in the episode, if you want to know more about the field of digital neurotherapeutics and the latest trends in that regard, have a look at Rock Health (and subscribe to their newsletter) and MobiHealthNews. You can get in touch with Naveed through LinkedIn or by email: naveed.ejaz@mindmaze.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don't hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram!

In this episode, Bryan talks to Dr. Suzanne Jasberg about Transcranial Magnetic Stimulation (TMS). TMS is being used to help people struggling with treatment resistant depression, along with other mental health conditions.  Dr. Jasberg talks more about what TMS is, how it works, and who qualifies for it. Dr. Jasberg is a psychiatrist in the Center for Neurotherapeutics at PrairieCare.  As always, take what serves you from this conversation - and leave the rest. (This podcast is not meant to replace therapy. If you feel you need it, we encourage you to reach out to a licensed mental health professional)

In this episode, our guest speaker Dr. Diana Castro, Associate Professor of Pediatrics, Neurology and Neurotherapeutics at the University of Texas Southwestern shares her extensive clinical knowledge and discusses the clinical, diagnostic and medical landscape in DMD, as well as management approaches in the care of DMD. Diana Castro, M.D., is a neurologist at Children's Health℠ who specializes in pediatric neurology and neuromuscular medicine. She is also an assistant professor of pediatrics and neurology and neurotherapeutics at UT Southwestern Medical Center. She is the co-director of the Muscular Dystrophy Association Clinic in Dallas and is involved in multiple research protocols for spinal muscular atrophy (SMA) and Duchenne muscular dystrophy in the pediatric population. PTC Therapeutics has provided financial compensation to Dr Castro for the time to conduct this interview. US-DMD-0252 I 09/28/21 Trademarks, registered or otherwise, are the property of their respective owner(s). © 2021 PTC Therapeutics, Inc. All Rights Reserved. See acast.com/privacy for privacy and opt-out information.

This Podcast is for educational purposes only not intended to treat cure diagnose or prevent sickness illness disease or mental health issues if you are making any lifestyle changes to your health and wellness routine for yourself and family consult with your medical doctor first. #holistichealth #wellness #holistichealing #holisticmedicine #alternativehealth #alternativehealing #alternativemedicine #Autismspectrumdisorder Reference: Autism Spectrum Disorder: Communication Problems in Children" (Links to an external site.). NIDCD. 18 August 2015 American Psychiatric Association (2013). "Autism Spectrum Disorder. 299.00 (F84.0)". Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Publishing. pp. 50–59. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. Washington DC, USA Arnold, L. E., Lofthouse, N., & Hurt, E. (2012). Artificial food colors and attention- deficit/hyperactivity symptoms: conclusions to dye for. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 9(3), 599–609. doi:10.1007/s13311-012- 0133-x Compart P. J. (2013). The pathophysiology of autism. Global advances in health and medicine, 2(6), 32– 37. doi:10.7453/gahmj.2013.092 Cell Press. (2016, June 9). Autism is not just a disorder of the brain, mouse study suggests. ScienceDaily. Retrieved November 20, 2019 from w,ww.sciencedaily.com/releases/2016/06/160609134247.htm (Links to an external site.) --- Send in a voice message: https://anchor.fm/rdlc/message

Arguably, sleep serves as the most crucial keystone habit of your consistent daily experience. Come with me on a journey of exploring sleep hygiene, sleep challenges, and how to start improving yours. Crick, F. & Mitchinson, G. (1995). REM sleep and neural nets. Behavioral Brain Research, Jul-Aug, 69 (1–2), p. 146-155. https://www.ohsu.edu/brain-institute/understanding-sleep-disorders Thorpy M. J. (2012). Classification of sleep disorders. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 9(4), 687–701. https://doi.org/10.1007/s13311-012-0145-6

The efforts to develop drugs for neurologic and psychiatric conditions has been plagued with failure. Herophilus is combining organoids derived from patient stem cells along with machine learning to gain new insight into the biology underlying these diseases and discover and develop more effective drugs. We spoke to Saul Kato, co-founder and CEO of Herophilus, about the drug development challenges for these diseases, how his company is using organoids and machine learning to better understand how to target them, and its growing pipeline therapeutic candidates.

กัญชา สมุนไพรที่อยู่คู่กับมนุษย์มาอย่างช้านาน ทั้งในเรื่องของการใช้เพื่อสันทนาการ และการนำประโยชน์มาใช้ในทางการแพทย์ แล้วกัญชานั้นแบ่งออกเป็นกี่สายพันธุ์ มีข้อดี ข้อเสีย หรือข้อควรระวังในการใช้อย่างไรบ้าง มาติดตามได้ในรายการ Dr.Amp Podcast เรื่องเล่าสุขภาพดี กับ หมอแอมป์ ตอน "กัญชา คุณค่าสมุนไพรจากธรรมชาติ" โดย นพ. ตนุพล วิรุฬหการุญ -ประธานเจ้าหน้าที่ปฏิบัติการ และ ผู้อำนวยการ BDMS Welness Clinic -ผู้อำนวยการ RoyalLife โรงพยาบาลกรุงเทพ -นายกสมาคมแพทย์ฟื้นฟูสุขภาพและส่งเสริมการศึกษาโรคอ้วน กรุงเทพ (BARSO) สามารถค้นหารายชื่อแพทย์ที่ผ่านการอบรมหลักสูตรการใช้กัญชาที่กรมการแพทย์ หรือ กรมการแพทย์แผนไทยและการแพทย์ทางเลือกให้การรับรองได้ที่: http://hemp.fda.moph.go.th/FDA_MARIJUANA/SAS/VISIT_DOCTOR

Dr. Porter is the Director of Dementia, Alzheimer’s disease, and Neurocognitive Disorders at the Pacific Brain Health Center at Pacific Neuroscience Institute (PNI) located at Providence Saint John’s Health Center in Santa Monica, CA. In addition, she is a Professor of Neurosciences, Department of Translational Neurosciences and Neurotherapeutics at John Wayne Cancer Institute. https://www.pacificneuroscienceinstitute.org/about-us/our-team/ | (310) 582-7640

In this episode, Dr. Kesari talks about his 20 years of working with patients suffering a deadly disease. He speaks about how his patients and their families are like his own and how his connection to them gave him a deep understanding of living and dying.Dr. Santosh Kesari is a board-certified neurologist and neuro-oncologist and is currently Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, Saint John’s Cancer Institute. He is also Director of Neuro-oncology at Pacific Neuroscience Institute, Providence Saint John’s Health Center and Providence Little Company of Mary Medical Center Torrance and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.Dr. Kesari is ranked among the top 1% of neuro-oncologists and neurologists in the nation, according to Castle Connolly Medical Ltd and an internationally recognized scientist and clinician. He is a winner of an Innovation Award by the San Diego Business Journal. He is on the advisory board of American Brain Tumor Association, San Diego Brain Tumor Foundation, Chris Elliott Fund, Nicolas Conor Institute, Voices Against Brain Cancer, and Philippine Brain Tumor Alliance. He has been the author of over 250 scientific publications, reviews, or books. He is the inventor on several patents and patent applications, and founder and advisor to many cancer and neurosciences focused biotech startups. In addition, he is a member of the Los Angeles Biomedical Research Institute.Dr. Kesari has had a long-standing interest in cancer stem cells and studies their role in the formation of brain tumors and resistance to treatment. He believes that in order to cure patients with brain tumors we first need to gain a better molecular and biological understanding of the disease. A physician/scientist, Kesari harnesses his experience in surgery, chemotherapy, immunotherapy, radiation therapy and novel devices to help develop Precision Therapeutic Strategies that will advance medicine to a new stage in the battle against brain tumors and eradicate the disease.HighlightsDr. Kesari graduated from University of Pennsylvania, School of Arts and Sciences in 1992 and earned a PhD degree in molecular biology and a MD from the University of Pennsylvania, School of Medicine.He completed his residency in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School and his neuro-oncology fellowship at the Dana-Farber Cancer Institute in Boston. He was previously assistant professor of neurology at Harvard Medical School/Dana-Farber Cancer Institute/Brigham and Women’s Hospital and then professor of neurosciences at UC San Diego. He is a member of the Society of Neuro-Oncology, American Society of Clinical Oncology, Indian Society of Neuro-Oncology, American Neurological Association, and American Academy of Neurology.Support the show (https://healgrief.org/donations/)

In this episode, let's talk about what ADHD is, how common autism and ADHD are in individuals, and the cause and impact these co-occurring conditions have on individuals. References: Autism and ADHD. (2017). Autism Spectrum Australia. Retrieved March 24, 2021. Casanova, M.F., Frye, R.E., Gillberg, C., & Casanova, E.L. (2020). Editorial: Comorbidity and autism spectrum disorder. Frontiers in Psychiatry. doi: 10.3389/fpsyt.2020.617395. Chen, M. H., Wei, H. T., Chen, L. C., Su, T. P., Bai, Y. M., Hsu, J. W., ... & Chen, Y. S. (2015). Autistic spectrum disorder, attention deficit hyperactivity disorder, and psychiatric comorbidities: A nationwide study. Research in Autism Spectrum Disorders, 10, 1-6. Davis, N. O., & Kollins, S. H. (2012). Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics, 9(3), 518-530. Gargaro, B. A., May, T., Tonge, B. J., Sheppard, D. M., Bradshaw, J. L., & Rinehart, N. J. (2014). Using the DBC-P Hyperactivity Index to screen for ADHD in young people with autism and ADHD: A pilot study. Research in Autism Spectrum Disorders, 8(9), 1008-1015. Matson, J.L. (2016). Comorbid conditions among children with autism spectrum disorders. Berlin, Germany: Springer. National Institute for Health and Care Excellence (2018). Attention deficit hyperactivity disorder: Diagnosis and management. London: NICE. Retrieved 8 August 2019 from nice.org.uk/guidance/ng87. Thapar, A., Cooper, M., Eyre, O., & Langley, K. (2013). Practitioner review: What have we learnt about the causes of ADHD? Journal of Child Psychology and Psychiatry, 54(1), 3-16. doi: 10.1111/j.1469-7610.2012.02611.x. Van Steijn, D. J., Oerlemans, A. M., Van Aken, M. A., Buitelaar, J. K., & Rommelse, N. N. (2014). The reciprocal relationship of ASD, ADHD, depressive symptoms and stress in parents of children with ASD and/or ADHD. Journal of Autism and Dvelopmental Disorders, 44(5), 1064-1076. Zablotsky, B., Bramlett, M. D., & Blumberg, S. J. (2017). The Co-Occurrence of Autism Spectrum Disorder in Children With ADHD. Journal of Attention Disorders, 1087054717713638. ADHD links: https://kidshealth.org/en/teens/adhd.html https://raisingchildren.net.au/for-professionals/mental-health-resources/adhd-ocd-odd Autism and ADHD support: https://www.adhdsupportaustralia.com.au/adhd-listings/autism-community-network/ Support networks for ADHD: http://www.parentsforadhdadvocacy.com.au NSW: http://www.adhdsupportaustralia.com.au/ www.macquarieadhd.org.au www.adultadhd.org.au ACT: www.addact.org.au WA: www.adhdwa.org VIC: www.adhdsupport.org.au QLD: https://www.meetup.com/Brisbane-ADHD-Meetup/ For more information, head over to Aspect Australia - www.autismspectrum.org.au. Disclaimer: I'm not a professional, just a student with a passion for autism.

"Sitting is the New Smoking!" What a statement from Dr. Salman Bhai, Assistant Professor in the Department of Neurology and Neurotherapeutics at UTSW Medical Center and Faculty Member at the Institute of Exercise and Environmental Medicine (IEEM) at Texas Health Presbyterian Hospital Dallas. We explore movement and muscles from someone who is both credentialed, knowledgable, and passionate about the topic. This is a definite "don't miss" episode!Then, Sherry Cusumano, Director of Community Education and Clinical Development at Medical City Green Oaks Hospital joins us to talk about a big, but little-known topic: Compassion Fatigue. If you have a special needs child, an aging parent who requires regular care, or even if Covid-19 has come calling, you'll want to hear Sherry's explanation of this very important mental health issue that has been exacerbated during the pandemic. See acast.com/privacy for privacy and opt-out information.

SummaryFor thousands of years indigenous Americans have used hallucinogenic mushrooms in religious ceremonies as entheogens. These mushrooms are now known to contain psilocybin, a small molecule with profound mind-altering properties. While many cultures have understood the therapeutic potential of psilocybin for thousands of years, most modern countries are only now accepting psilocybin’s potential as medicine. Morbidity and MortalityThe profound mind-altering effects of psilocybin should not be under-estimated and have led to many fatal accidents. However, psilocybin is very safe from a purely toxicological standpoint. The LD50 (dose at which half of people die) is estimated to be 6g or 1000 times the normal recreational dose. Most all reported psilocybin fatalities have involved significant co-ingestions. StoryThe Aztecs called hallucinogenic mushrooms “tonanacatl” meaning “God’s Flesh”. In 1519 when Spain conquered the Aztec Empire, they banned cultural practices like the use of hallucinogenic mushrooms. Years later, in 1970 the United Nations required all member nations to ban psilocybin. However, this attitude is finally changing. Oregon became the first state to legalize psilocybin in 2020. However, it remains federally illegal. Key Points1. Psilocybin is a small molecule found in the fruiting bodies (mushrooms) of hundreds of species of fungi around the world2. It is very similar to the neurotransmitter serotonin and is an agonist at various serotonin receptors, most importantly 5HT2A.3. Though it is currently DEA schedule 1, psilocybin has numerous potential health benefits, most notably in the treatment of multiple psychiatric disorders like depression and substance abuse.4. Those who have ever used psilocybin are probably less likely to commit violent crimes and often report enduring beneficial effects. Feeling of interconnectedness with other people, nature, and the universe are regularly reported by users.5. Some things I forgot to say in the podcast: - Make sure you get psilocybin from a trustworthy source. Fake and adulterated products are very common. - Calling a friend or loved one can be a great way to get through a "bad trip"- Everyone has a different metabolism. Some will get profound effects from a small dose while other may need larger doses.- Micro-dosing (taking about 1/10 a normal dose) is often done on an almost daily basis to help with depression, anxiety, and to improve creativity. Think about it like a daily antidepressant. This is a sub-hallucinogenic dose. References-       Johnson, M. W., & Griffiths, R. R. (2017). Potential Therapeutic Effects of Psilocybin. Neurotherapeutics:14(3), 734–740. -       Hendricks PS, Crawford MS, Cropsey KL, Copes H, Sweat NW, Walsh Z, Pavela G. The relationships of classic psychedelic use with criminal behavior in the United States adult population. J Psychopharmacol. 2018;32(1):37-48. -       Neavyn MJ and Carey JL. Hallucinogens. GoldFrank’s Toxicology. 2019.-       Wikipedia. Psilocybin, Psilocin, Serotonin, Psilocybin Decriminalization in the United States.-       https://www.dea.gov/drug-scheduling-       Mandrake K. The Psilocybin Mushroom Bible: The Definitive Guide and Growing and Using Magic Mushrooms. 2016.

At this recording, the COVID-19 pandemic is raging with nearly 100 million people affected and over 2.1 million dead.  Recently available COVID-19 vaccines are providing some much needed hope. Vaccinations have been extremely effective in saving people from fatal diseases but many people living with multiple sclerosis have questions about whether COVID-19 vaccines are safe and effective for them. This episode explains the two major COVID-19 vaccines types — mRNA and adenovirus — and what people with should know about them.  This episode also covers different types of vaccines people with multiple sclerosis should avoid and which vaccines are safe. Experts tackle questions like whether vaccines can trigger MS relapses and review specific vaccines such as measles-mumps-rubella (MMR), chicken pox (varicella), hepatitis B and influenza (flu). Multiple sclerosis disease-modifying therapies (DMTs) can suppress the immune system and potentially impact whether a vaccine will be protective or not. Existing info on each MS medication type is discussed. Timing of vaccinations and medication dosing strategies covered. Vaccines as a strategy to prevent or treat multiple sclerosis are explored. Barry Singer MD, Director of The MS Center for Innovations in Care, interviews: Anne Cross MD is Professor of Neurology at Washington University in St. Louis and Dr. John Trotter MS Chair in Neuroimmunology. Her leading work in B cells in multiple sclerosis was recently recognized with the 2019 John Dystel Prize for MS Research. Amit Bar-or MD, FRCP is Professor of Neurology at University of Pennsylvania Perelman School of Medicine. He serves as Director of the Center for Neuroinflammation and Neurotherapeutics, and Chief of the Division of Multiple Sclerosis and Related Disorders. He runs a cellular and molecular neuroimmunology lab focused on injury and repair of the human central nervous system. Visit mslivingwell.org for more information. Share your MS story on ICanWithMS.org

Is your doctor going to be tripping on mushrooms? Sicker Than Your Average Health Show (STYAHS) brings you our third episode! Josh & Preet look at the latest developments that may possibly make magic mushrooms available in Canada, before comparing and contrasting legalization when it comes to psilocybin versus cannabis.Join us as we dig into the health headlines you already know and tell you more about the ones you don't.CreditsEditor: Mack BrittonLogo design: Brad HartMusic: I Got a Funky Feeling by Calmer Palmer thanks to RitualMusic.comLinkshttps://boingboing.net/2020/12/08/canadas-health-minister-says-health-care-professionals-can-consume-magic-mushrooms.htmlhttps://youtu.be/XBEas8MGzd0https://thetyee.ca/News/2020/12/10/Health-Canada-Removes-Barrier-Psilocybin/https://merryjane.com/news/17-canadian-mental-health-professionals-are-now-allowed-to-trip-on-shrooms-for-workhttps://www.canada.ca/en/health-canada/services/substance-use/controlled-illegal-drugs/magic-mushrooms.htmlhttps://www.vice.com/en/article/4adw4w/canada-is-allowing-people-with-depression-to-do-psychedelic-mushroomshttps://podcasts.apple.com/ca/podcast/magic-mushrooms-trip-through-the-science/id1051557000?i=1000502003842https://www150.statcan.gc.ca/n1/pub/82-003-x/2020002/article/00002-eng.htmhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710088/https://www.cbc.ca/news/canada/london/some-doctors-therapists-get-health-canada-permission-to-use-magic-mushrooms-1.5834485https://podcasts.apple.com/ca/podcast/science-history-psychedelic-therapy-feel-good-friday/id1034035933?i=1000496600895https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813425/https://therapsil.ca/bibliography/Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders by Kelan Thomas, Benjamin Malcolm & Dan Lastra in journal of psychoactive drugs  Available at: https://doi.org/10.1080/02791072.2017.1320734Potential Therapeutic Effects of Psilocybin by Matthew W. Johnson & Roland R. Griffiths in Neurotherapeutics (2017)The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant by Ben Sessa in Psychopharmacology (2018)Psychedelic Psychiatry's Brave New World by David Nutt, David Erritzoe, and Robin Carhart-Harris in Cell (2020) Available at:  https://doi.org/10.1016/j.cell.2020.03.020

Lecture SummaryKeeping your brain healthy pays dividends. It can also help prevent dementia down the road. Join me on an interesting discussion regarding how to keep your brain working optimally for years and years.Key Points- exercise your brain, think and challenge yourself mentally constantly.- exercise your body, this has been well studied and will help prevent dementia- eat good food- get adequate sleep- avoid illicit and pharmaceutical medications that impair thinking. If used long term these will predispose you to dementia.- have a purpose and give back- engage with other people and society. - protect your eyes, ears, and other sensesReferences- Cabral et al. Exercise for Brain Health: An Investigation into the Underlying Mechanisms Guided by Dose. Neurotherapeutics. 2019.- Erickson et al. Physical Activity, Brain Plasticity, and Alzheimer Disease. Archives of Medical Research. 2012.- Blackwell, L., Dweck, C., & Trzesniewski, K. (2002). Achievement across the adolescent transition: A longitudinal study and an intervention. Manuscript in preparation.- Dweck, C., & Leggett, E. (1988). A social-cognitive approach to motivation and personality. Psychological Review, 95,256-273.- Wikipedia. dementia, donepezil, memantine, blue zone.- Uptodate. Evaluation of Cognitive Impairment in Adults and Treatment of Dementia.- Montreal Cognitive Assessment. Available at (https://www.parkinsons.va.gov/resources/MOCA-Test-English.pdf)- Sirishinha Stitaya. The potential impact of gut microbiota on your health: Current status and future challenges. Asian Pac J Allergy Immunol. 2016.- Veerman et al. Television viewing time and reduced life expectancy: a life table analysis. BMJ. 2012.- Ray et al. Dementia and hearing loss: A narrative review. Maturitas. 2019.

Dr. Erik Won's company: Wave NeuroSpecial Operations Care Fund (SOC-F) and Tomahawk Charitable Solutions to Support Leader in Neurotherapeutics to Provide Breakthrough Treatment Technology for Special Operations VeteransZap: How Electric Therapy Is Curing Navy SEALs of PTSDTraumatic Brain Injury, Post Traumatic-Stress, Depression, and Anxiety

The Science of Mood And Your Microbiome | This episode is brought to you by Thrive Market and JoovvWe often hear about food in the context of physical health—eating for a strong heart, healthy weight, and glowing skin. But what about the other impacts of food, like how it makes us feel emotionally and mentally? The growing field of nutritional psychiatry is shedding light on this profound connection, and it’s something I’m personally really excited about. On this episode of The Doctor’s Farmacy, I was so happy to talk to Dr. Uma Naidoo about the connection between food and mood, looking at how what we eat impacts everything from anxiety and depression to ADHD, and more. Michelin-starred chef David Bouley described Dr. Uma Naidoo as the world’s first “triple threat” in the food as medicine space. She is a Harvard trained psychiatrist, professional chef, and Nutrition Specialist. Her niche work is in nutritional psychiatry and she is regarded both nationally and internationally as a medical pioneer in this more newly recognized field. In her role as a Clinical Scientist, Dr. Naidoo founded and directs the first hospital-based clinical service in Nutritional Psychiatry in the US. She is the Director of Nutritional and Lifestyle Psychiatry at Massachusetts General Hospital (MGH) and Director of Nutritional Psychiatry at the Massachusetts General Hospital Academy while serving on the faculty at Harvard Medical School. Dr. Naidoo is the author of the recently released book, This is Your Brain on Food. In her book, she shows the cutting-edge science explaining the ways in which food contributes to our mental health and how a sound diet can help treat and prevent a wide range of psychological and cognitive health issues.This episode is brought to you by Thrive Market and Joovv.Our mitochondria get weaker and less abundant as we get older, plus lots of things in our lives like stress, bad food, and toxins damage them over time. But a modality called red light therapy helps me support healthier mitochondria and fight inflammation. I use Joovv red light therapy devices. If you want to check out Joovv’s various red light therapy devices for yourself just head over to joovv.com/farmacyRight now, Thrive is offering all Doctor's Farmacy listeners an amazing deal - When you sign up for a new membership, you can get up to $20 in shopping credit that goes towards all your favorite natural food, body, and household items. And any time you spend more than $49 you’ll get free carbon-neutral shipping. Just head over to thrivemarket.com/Hyman to check out all their awesome products. Here are more of the details from our interview: Dr. Naidoo’s cancer diagnosis and how she used food to help her anxiety while undergoing treatment (7:49)How Dr. Naidoo came to think about nutritional psychiatry (10:31)America’s mental health crisis and reliance on medications to treat anxiety, depression, etc. (14:23)Creating a personalized nutritional plan to treat mental illness (17:47)The relationship between gut health, diet, anxiety, depression, ADHD, OCD, etc. (20:15)The correlation between anxiety, depression, gluten, omega-3 fats, and folate (21:41)How the food we eat can drive neuroinflammation (25:20)Is food driving divisiveness in our society? (39:00)Mental health issues in children (44:01)The benefits of eating a diversity of vegetables and fruits (52:42)Get Dr. Naidoo’s book, This Is Your Brain on Food: An Indispensable Guide to the Surprising Foods that Fight Depression, Anxiety, PTSD, OCD, ADHD, and More, at https://book.umanaidoomd.com/Learn more about Dr. Naidoo at https://umanaidoomd.com/ and follow her on Facebook @DrUmaNaidoo, on Instagram @DrUmaNaidoo, and on Twitter @DrUmaNaidooLearn more about the research cited in this episode:Persistent microbiome alterations modulate the rate of post-dieting weight regain https://genie.weizmann.ac.il/pubs/2016-christoph-nature-november.pdfLach, G., et al., Anxiety, Depression, and the Microbiome: A Role for Gut Peptides. Neurotherapeutics, 2018. 15(1): p. 36-59. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794698/Hoban, A.E., et al., The microbiome regulates amygdala-dependent fear recall. Mol Psychiatry, 2018. 23(5): p. 1134-1144. https://www.nature.com/articles/mp2017100 See acast.com/privacy for privacy and opt-out information.

Host: Jennifer Caudle, DO Guest: Amit Bar-Or, MD, FRCP, FAAN, FANA Joining Dr. Jennifer Caudle to discuss the latest research furthering our understanding and treatment of multiple sclerosis is Dr. Amit Bar-Or, Chief of the Multiple Sclerosis Division and Director for the Center of Neuroinflammation and Neurotherapeutics at Penn Medicine. Could these recent findings finally help us solve some of the unanswered questions of multiple sclerosis?

Host: Jennifer Caudle, DO Guest: Amit Bar-Or, MD, FRCP, FAAN, FANA Joining Dr. Jennifer Caudle to discuss the latest research furthering our understanding and treatment of multiple sclerosis is Dr. Amit Bar-Or, Chief of the Multiple Sclerosis Division and Director for the Center of Neuroinflammation and Neurotherapeutics at Penn Medicine. Could these recent findings finally help us solve some of the unanswered questions of multiple sclerosis?

How does the clinic influence the bench? Joe, Jeremy, and Audrey are joined by Dr. Peter Tsai Assistant Professor in the departments of Neurology and Neurotherapeutics, Neuroscience, Pediatrics, and Psychiatry at UT South Western. Learn how Dr. Tsai's experience in the clinic led him down a path of investigating the surprising role of the cerebellum in autism spectrum disorder and how Dr Tsai's findings in the lab could impact the development of future treatments.

Charles L. Raison, MD, returns to the Psychcast to conduct a Masterclass on psychedelics for patients with major depressive disorder. Dr. Raison, professor of psychiatry at the University of Wisconsin–Madison, previously conducted a Masterclass on the risks and benefits of antidepressants. He disclosed that he is director of translational research at the Usona Institute, also in Madison. Later, Renee Kohanski, MD, raises questions about the felony child abuse case of pediatric emergency department doctor John Cox. Takeaway points Psychedelics are a range of compounds that share a common mechanism as agonists at the postsynaptic 5-HT2A serotonin receptor. Psychedelic agents have a novel therapeutic quality. Studies suggest that a few or even one exposure to a psychedelic compound, which has a short-term biological effect, leads to long-lasting therapeutic effect, such as remission of mood disorder or change in personality characteristics. The clinical outcomes are mediated by the intensity of the psychedelic experience. A psychedelic experience is characterized by profound, rapid alterations in what is seen, sensed, felt, and thought. It often leads to personal growth with experiences of transcendence. Subjects in trials often report a “mystical experience” they describe as a sense of unity with the universe and understanding of one’s deeper purpose. Psychedelic experiences also are characterized by a difficulty in describing them with words. Because psychedelics are illegal substances, the traditional route of pharmaceutical companies’ funding the research for clinical trials is not available. Organizations such as Usona Institute and MAPS (Multidisciplinary Association for Psychedelic Studies) are leading the way. The Food and Drug Administration has granted psilocybin a “breakthrough therapy designation” for the treatment of major depressive disorder. Summary Psilocybin, lysergic acid diethylamide (LSD), mescaline, ayahuasca (active ingredient: N,N-dimethyltryptamine [DMT]), and 3,4-methylendioxy-methamphetamine (MDMA) are all classified as psychedelics. Psychedelics have been used for thousands of years for spiritual ceremonies. Psychedelics came to the attention of medicine and science after 1943 when Albert Hofmann, PhD, a chemist at a Sandoz Lab in Basel, Switzerland, synthesized LSD and accidentally ingested it, serendipitously identifying its mind-altering properties.  Until 1970, psychedelics were widely used in clinical research, and more than 1,000 academic papers about their use were published. For example, psychedelics were used as a model for schizophrenia and helped identify the role of serotonin in psychosis. They also were studied to treat addiction and as a treatment for existential anxiety in cancer. In 1971, psychedelics were declared illegal under the U.N. Convention on Psychotropic Substances. Researchers returned to psychedelics in the 2000s, examining a variety of uses, including the capability to reliably induce psychedelic experience in healthy normal volunteers (no previous psychiatric diagnosis) and promote emotional well-being in healthy normal volunteers. The role of psychedelics as medicine are once again being studied in a variety of contexts, such as mood disorders, PTSD, addiction, and phase-of-life problems. Most notable from the research is the capability of psychedelic compounds to induce long-lasting effects on personality, mood disorders, and PTSD after one or a few ingestions. What is remarkable is how the therapeutic effect remains long after the biological presence of the compound is gone from the body. The clinical outcomes are mediated by the intensity of the psychedelic experience. The Usona Institute, a medical research organization, started as a nonprofit to advance the research into psychedelics needed for the FDA to approve psychedelics as a treatment. Because psychedelics are still illegal, the traditional route of pharmaceutical companies funding this type of research is not available. The FDA has granted psilocybin a “breakthrough therapy designation” for the treatment of major depressive disorder. The breakthrough therapy designation “indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies.” The breakthrough therapy designation is for major depressive disorder, not for treatment-resistant depression, suggesting that the FDA recognizes the shortcomings of current treatments for depression. References Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics. 2017 Jul;14(3):734-40. Griffiths RR et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning in trait measures of prosocial attitudes and behaviors. J Psychopharmacol. 2018 Jan;32(1):49-69. Johnson MW et al.  Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017 Jan;43(1):55-60. Griffiths RR et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016 Dec;30(12):1181-97. Rozzo M. Book review: “‘How to Change Your Mind.” Columbia Magazine. 2018 Fall. *  *  *   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com

The sole FDA approved indication for clobazam is as a therapeutic adjunct in Lennox Gastaut Syndrome. But as more and more clinicians publish their experience with the off-label success of certain therapies, we may see new indications for this and other pharmacologic agents in the treatment of neurologic disease. Produced by James E. Siegler. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. Music courtesy of Chris Zabriskie, Milton Arias, and John Bartmann. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Schmidt D, Rohde M, Wolf P and Roeder-Wanner U. Clobazam for refractory focal epilepsy. A controlled trial. Archives of neurology. 1986;43:824-6. Keene DL, Whiting S and Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci. 1990;17:317-9. Remy C. Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia. 1994;35 Suppl 5:S88-91. Montenegro MA, Cendes F, Noronha AL, Mory SB, Carvalho MI, Marques LH and Guerreiro CA. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia. 2001;42:539-42. Ng YT and Collins SD. Clobazam. Neurotherapeutics. 2007;4:138-44. Montenegro MA, Arif H, Nahm EA, Resor SR, Jr. and Hirsch LJ. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center. Clin Neuropharmacol. 2008;31:333-8. Mahmoud SH and Rans C. Systematic review of clobazam use in patients with status epilepticus. Epilepsia Open. 2018;3:323-330. Bresnahan R, Martin-McGill KJ, Williamson J, Michael BD and Marson AG. Clobazam add-on therapy for drug-resistant epilepsy. The Cochrane database of systematic reviews. 2019;10:CD004154. YOUTUBE EXCERPTS (shared via fair use) Kathryn Davis, MD (Hospital of the University of Pennsylvania): https://www.youtube.com/watch?v=XInZ7Y0lgKg Patty McGoldrick, NP, MPA (Beth Israel Deaconness Medical Center/Roosevelt Hospital): https://www.youtube.com/watch?v=sE2BkYXqxJs&t=14s

In this episode of Discussions in Spinal Cord Injury Science (DiSCIS), Rachel Tappan, PT, DPT interviews Dr. Monica Perez, Scientific Chair of Arms and Hands Lab at the Shirley Ryan Ability Lab in Chicago. The discussion focuses on neuromodulation and Dr. Perez's work. For further reading, check out: Christiansen L, Perez MA. Targeted-plasticity in the corticospinal tract after human spinal cord injury. Neurotherapeutics. 2018;15:618-627. The Spinal Cord Injury Special Interest Group is a part of the Academy of Neurologic Physical Therapy - www.neuropt.org.

Host Dr. Larry Newman discusses medication overuse headache with Dr. Todd Schwedt, a Neurologist at the Mayo Clinic, and Deborah Friedman, a Professor of Neurolgoy and Neurotherapeutics at the University of Texas - Southwestern.

Egyptian scriptures from 1200 BCE describe painful, migraine-like headaches, so we know the disorder has afflicted people for at least three thousand years. Still, the condition continues to mystify us today. Anne Hoffman is a reporter, a professor, and a chronic migraine sufferer. She spent the past year tracing the history of migraines, hoping to discover clues about a treatment that actually works for her. The journey took her in some interesting directions. One common theme she found? A whole lot of stigma. Credits Hosts: Alexis Pedrick and Elisabeth Berry Drago Senior Producer: Mariel Carr Producer: Rigoberto Hernandez Reporter: Anne Hoffman Photo illustration by Jay Muhlin Additional audio production by Dan Drago Music Theme music composed by Zach Young. "Valantis" and "Valantis Vespers" by Blue Dot Sessions, courtesy of the Free Music Archive. Additional music courtesy of the Audio Network. Research Notes Interviews Matthew Crawford, Doan Fellow, Science History Institute. Margaret Heaney, professor of neurobiology, Columbia University Irving Medical Center. Joanna Kempner, sociologist and author of Not Tonight: Migraine and the Politics of Gender and Health. Anne MacGregor, medical researcher and clinician. Brian McGeeney, assistant professor of neurology, Boston University School of Medicine.  Sources Brooklyn Museum, Elizabeth A. Sackler Center for Feminist Art. “Hildegarde of Bingen.” McClory, Robert. “Hildegard of Bingen: No Ordinary Saint.” National Catholic Reporter, March 24, 2012. Meares, Hadley. “The Medieval Prophetess Who Used Her Visions to Criticize the Church.” Atlas Obscura, July 13, 2016. PBS Frontline. “Hildegard’s Scivias.” Songfacts. Für Hildegard Von Bingen. Wikipedia. “Scivias.” Last modified October 23, 2018, https://en.wikipedia.org/wiki/Scivias. Cannabidiol (CBD): Bazelot, Michaël, Chen Tong, Ibeas Bih, Dallas Mark, Clementino Nunn, Alistair V. W. Whalley Benjamin. “Molecular Targets of Cannabidiol in Neurological Disorders.” Neurotherapeutics 12 (2015): 699–730. Chen, Angus. “Some of the Parts: Is Marijuana’s ‘Entourage Effect’ Scientifically Valid?” Scientific American, April 20, 2017. Grinspoon, Peter. “Cannabidiol (CBD)—What We Know and What We Don’t.” Harvard Health Blog, Harvard Health Publishing, Harvard Medical School, August 24, 2018. Science Vs. “CBD: Weed Wonder Drug?” Podcast audio, November 15, 2018.. Migraine: Kempner, Joanna. “The Birth of the Dreaded ‘Migraine Personality.’” Migraine Again, November 30, 2017. Neighmond, Patti. “Why Women Suffer More Migraines Than Men.” Shots: Health News from NPR, National Public Radio, April 16, 2012. Peterlin, B. Lee, Saurabh Gupta, Thomas N. Ward, and Anne MacGregor. “Sex Matters: Evaluating Sex and Gender in Migraine and Headache Research.” Headache 51(6) (2011): 839–842. Sharkey, Lauren. “Why Don’t We Know More about Migraines?” BBC Future, British Broadcasting Corporation, July 2, 2018. Wikipedia. “Aretaeus of Cappadocia.” Last modified December 6, 2018. https://en.wikipedia.org/wiki/Aretaeus_of_Cappadocia. Cannabis for Migraine: Mandal, Ananya. “Migraine History.” News-Medical, August 23, 2018. MDede. “Are Cannabinoids and Hallucinogens Viable Treatment Options for Headache Relief?” Neurology Reviews 22(5) (2014): 22–23. Available at MDedge, Clinical Neurology News. Archival: Grass—The History of Marijuana. Directed by Ron Mann. Toronto: Sphinx Productions, 1999. Hildegard of Bingen. Directed by James Runcie. London: British Broadcasting Corporation, 1994. Reefer Madness. Directed by Louis J. Gasnier. Los Angeles: George A. Hirliman Productions, 1938.

Caros amigos do Microbiando, chegamos ao episódio de número 10!! Primeiramente gostaríamos de agradecer a todos que nos ouvem desde o início e compartilham conosco seus ouvidos e atenção. Nosso muito obrigado! E no episódio de hoje, conduzido pelo prof. Mateus Godoy, falamos sobre um bioaumento de bactérias Pseudomonas aeruginosa já presentes em reservatórios de petróleo para a produção de uma classe de biomoléculas in situ, os biosurfactantes, que auxiliam na recuperação do petróleo. Esse trabalho foi publicado em 2018 na Bioresource Technology, por um grupo chinês do Institute of Applied Ecology e da University of Chinese Academy of Sciences. O Microlitros de Notícias desse episódio está quase todo voltado para a relação entre microrganismos e neurônios. Conversamos sobre as semelhanças entre neurônios e biofilmes bacterianos; como a microbiota intestinal afeta processos de inflamação no cérebro; tivemos uma entrevista com Laura Cox, da Escola de Medicina de Harvard, falando sobre a interação microbiota-cérebro; e uma conversa com Nicolas Marchon, Gerente de Marketing Sênior para América Latina na Thermo Fisher Scientific. Na Filogenia da Ciência, falaremos sobre a pesquisadora Monserrate Román Cerezo, Microbiologista Chefe do projeto de controle ambiental e sistema de suporte vital na NASA.   Tópicos comentados nesse episódio Bioaumento Pseudomonas aeruginosa Biosurfactantes Recuperação do petróleo Biorremediação Enhanced Oil Recovery Microbial Enhanced Oil Recovery Tensão superficial e interfacial Biorreatores Biofilmes Microbiota Intestinal Inflamação no cérebro Eixo Microbiota-Cérebro Thermo Fisher Scientific Monserrate Román Cerezo Microbiologista da NASA XXIV Semana de Microbiologia e Imunologia da UFRJ Inscrições para o II Workshop on Inflammation, clique aqui   Referências desse episódio 2018. Zhao F, Li P, Guo C, Shi RJ, Zhang Y. Bioaugmentation of oil reservoir indigenous Pseudomonas aeruginosa to enhance oil recovery through in-situ biosurfactant production without air injection. Bioresour Technol. 2015. Arthur Prindle, Jintao Liu, Munehiro Asally, San Ly, Jordi Garcia-Ojalvo e Gurol M. Suel. Ion channels enable electrical communication in bacterial communities. Nature. Juliana Suyama Higa Biofilmes bacterianos: vivendo em comunidade. Departamento de Microbiologia, USP. 2015. Kim McDonald. Biologists Discover Bacteria Communicate Like Neurons in the Brain. UC San Diego. 2018. Manfredo Vieira, S. et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018. Lammert, C. et al. Cutting Edge: Critical Roles for Microbiota-Mediated Regulation of the Immune System in a Prenatal Immune Activation Model of Autism. The Journal of Immunology. 2018. Lach, G. et al.  Anxiety, Depression, and the Microbiome: A Role for Gut Peptides. NeuroTherapeutics. 2018. Rothhammer, V. et al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2009. Wikoff, W. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. PNAS. 2016. Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nature. 2018. Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, Kivisäkk P, Pierre IV, Hrishikesh L, Gandhi R, Cook S, Glanz B, Stankiewicz J, Weiner HL. A probiotic modulates the microbiome and immunity in multiple sclerosis.Ann Neurol. Wikipédia. Monserrate Román 2003. Department of NASA. Latina Scientist Keeps An Eye On Smallest Inhabitants Of Space.   Sobre o Podcast Microbiando A ideia do Microbiando é discutir artigos científicos de ponta em todas as áreas da microbiologia e imunologia. Vamos utilizar uma linguagem bem acessível para destrinchar esses artigos para vocês, mas sem perder o rigor científico e analítico necessário pa...

Show description/summary:1) Neurology® Clinical Practice: Barriers and Facilitators to ER Physician Use of the Test and Treatment for BPPV2) What’s Trending: New crowd-funding research initiative from ABFIn the first segment, Dr. Jim Siegler talks with Dr. Kevin Kerber and Dr. William Meurer about their Neurology® Clinical Practice article on ER physician use of the test and treatment for benign paroxysmal positional vertigo. In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. Robert Griggs and Jane Ransom on the new crowd-funding research initiative from the American Brain Foundation. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Siegler serves on the Resident and Fellow Section Team for Neurology, and has received research support from NIH (U10 StrokeNet grant, 2017-2018).Jane Ransom is Executive Director of the American Brain Foundation.Dr. Kerber received funding for travel from Elsevier Inc. and the American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; is a consultant for the American Academy of Neurology, University of California San Francisco (including work on a project funded by AstraZeneca), and Best Doctors, Inc.; receives research support from the NIH; received speaker honoraria from American Academy of Neurology and University of California San Francisco and loan repayment award from the NIH; reviewed legal records of Phil Pearsons, MD, JD and National Medical Consultants.Dr. Meurer serves as Decision Editor for the Annals of Emergency Medicine; serves as Methodology Statistics Reviewer for Academic Emergency Medicine; and has received research support from the Massey Foundation for TBI research. Dr. Griggs has served on scientific advisory boards for National Hospital Queen Square, Marathon Pharmaceuticals, Taro Pharmaceuticals, and Sarepta Pharmaceuticals; has served on the data monitoring and safety board for PTC Therapeutics, Inc.; serves on the editorial board for NeuroTherapeutics and Current Treatment Opinions in Neurology; serves as Correspondence Editor for Neurology; receives publishing royalties from Andreoli and Carpenter’s Cecil Essentials of Medicine (Eighth Edition, Elsevier), Cecil Textbook of Medicine (multiple editions, Elsevier), and Evaluation and Treatment of Myopathies (2014, Oxford); has consulted for Marathon, PTC Therapeutics, Sarepta, Taro Pharmaceuticals, Idera Pharmaceuticals, and Strongbridge Pharmaceuticals; receives data royalties and research support from Taro Pharmaceuticals and Marathon Pharmaceuticals; has received research support from NINDS (T32 NS07338, 5U01NS061799, 1R13NS084687), the FDA (R01 FD003923), Parent Project Muscular Dystrophy, Inc., and the Muscular Dystrophy Association; and is the recent past Chair of Executive Committee of the Muscle Study Group.

Show description/summary:1) Progressive rural-urban disparity in acute stroke care2) What's Trending: Upcoming changes regarding the Neurology® Resident & Fellow section 3) Topic of the Month: Neuromuscular topicsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 31, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Allison Willis about her paper on disparities in stroke care between rural and urban areas. Dr. Ted Burns talks with Dr. Eric Olsen regarding CRISPR at the 2016 AANEM meeting for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Merit Cudkowicz on amyotrophic lateral sclerosis (ALS). Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Allison Willis has served on the editorial board of Pharmacoepidemiology and Drug Safety; and has received research support from NIH/NINDS.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Eric Olson holds patents describing DMD gene editing.Dr. Merit Cudkowicz has served on the editorial board of DSMB AstraZenica (through Clintrex); has served on the editorial boards of Neurotherapeutics and JAMA Neurology; holds a patent for Metabolomics in ALS; receives publishing royalties from UpToDate; has been a consultant for Cytokinetics, Biogen-Idec, Voyager, Biohaven, Astrazenica, Genentech, Karyopharm, and Neuraltis; has received research support from NINDS, the Muscular Dystrophy Association, the ALS Association, and the ALS Finding a Cure Association; and has provided expert witness for defense (TEVA).All other participants have no disclosures.

1) Efficacy and safety of deflazacort versus prednisone and placebo for Duchenne muscular dystrophy2) e-Pearl topic: Alien limb phenomenon3) Topic of the month: How to examine and approach movement disordersThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Kelly Gwathmey interviews Dr. Robert Griggs about his the efficacy and safety of deflazacort versus prednisone for boys with Duchenne muscular dystrophy. Dr. Ilena George is reading our e-Pearl of the week about alien limb phenomenon. In the next part of the podcast Dr. Alberto Espay interviews Dr. Don Gilbert on the topic of tics.DISCLOSURES: Dr. Griggs serves as Correspondence Editor for Neurology®; serves as an editorial board member of NeuroTherapeutics and Current Treatment Opinions in Neurology; serves on the scientific advisory board for SAB for National Hospital Queen Square, Marathon Pharmaceuticals, PTC Therapeutics, Inc., DSMB, Taro Pharm and Sarepta Pharmaceuticals; is a consultant for Marathon, PTC Therapeutics, Sarepta, Taro Pharm and Idera Pharmaceuticals;receives royalties for data of previous studies from Taro Pharm and Marathon Pharmaceuticals; receives royalties from the publication of the books: Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition, Cecil Textbook of Medicine, multiple editions and Evaluation and Treatment of Myopathies; receives research support from Taro Pharma, Marathon Pharmaceuticals, Parent Project Muscular Dystrophy, Inc., Muscular Dystrophy Association, Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy and the NIH.Dr. George serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Gilbert serves on the scientific advisory boards of Investigations of Neuroplasticity Mechanisms in Autism Spectrum Disorders, the Berenson-Allen Center for Noninvasive Brain Stimulation, and Beth Israel Deaconess Medical Center; received honoraria from the Tourette Association of America, the Centers for Disease Control and Prevention, and the Hong Kong Society of Child Neurology and Developmental Pediatrics; received funding for travel for educational talks to physicians and affected patients and families;receives royalties from the publication of the book Movement Disorders in Childhood, 2nd edition; receives research support from Ecopipam Pharmaceuticals, Neurocrine Pharmaceuticals, EryDel Pharmaceuticals, and NIH; and has provided expert testimony for the Health Resources and Services Administration, Department of Health and Human Services regarding Division of Vaccine Injury Compensation Programs.

1) Quality improvement in neurology: Parkinson disease update quality measurement set2) What's Trending: Amyloid pathology and axonal injury after brain trauma 3) Topic of the month: George C. Cotzias Lecture at the AAN Meeting on antibody mediated disorders of the synapseThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Binit Shah interviews Drs. Janis Miyasaki and Stewart Factor about the AAN paper on new quality measures developed to improve outcomes for patients with Parkinson disease. Dr. Ted Burns is interviewing Dr. Ansgar Furst for our “What's Trending” feature of the week about his editorial on incidental findings for what's to come in amyloid plaques in traumatic brain injury. Dr. Alberto Espay interviews Dr. Josep Dalmau about his George C. Cotzias Lecture at the AAN Meeting on the topic of antibody mediated disorders of the synapse.DISCLOSURES: Dr. Miyasaki received honoraria and funding for travel from Teva Pharmaceutical Industries Ltd.; received funding for travel from Merz Pharmaceuticals, LLC; received travel honoraria from The International Parkinson Disease and Movement Disorders Society; is a consultant for Merz Pharmaceuticals, LLC; receives royalties from the publication of the book “Psychogenic Movement Disorders;” receives research support from PCORI: 2015-2018 and Parkinson Alberta.Dr. Factor served as an editorial board member of Neurotherapeutics; serves on the data safety monitoring board for Lundbeck, Inc; is a consultant for UCB; is a consultant and video reviewer for clinical trials for Avanir, Neurocrine and Auspex/Teva Pharmaceutical Industries Ltd.; receives royalties from the publications of the books “Parkinson's disease diagnosis and clinical management” and “Drug induced movement disorders;” gave expert testimony in Kmart trial (2014-2016); receives research support from Ceregene, Cynapsus, Sangamo, Teva Pharmaceutical Industries Ltd., Ipsen Pharmaceuticals, Inc., USWorldMeds, Allergen, Inc., Medtronics, Inc., Auspex, Genzyme Corporation, Michael J. Fox Foundation and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Dalmau serves as Editor of Neurology®: Neuroimmunology & Neuroinfammation; serves as an Editorial board member of Neurology® and UpToDate; receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests; is a consult for Advance Medical, receives research support from Euroimmun and the NIH; receives revenue from Euroimmun for the following tests: NMDA receptor autoantibody test, GABA(B)R autoantibody test, GABA(A)R autoantibody test, DPPX autoantibody test and Iglon5 autoantibody test.

Neuroscientist Amanda Duffy gets some surprising news about her brain when she volunteers to be a control in an MRI study. Amanda Marie Duffy is a graduate student at Brown University pursuing her Ph.D. in Neuroscience. Her research is focused on understanding mechanisms that underlie ALS disease progression and therapeutic intervention with the use of molecular, cellular, and behavioral techniques. In 2015, Amanda was named a fellow in the Society for Neuroscience’s Neuroscience Scholars Program. In 2014, Amanda was elected as Graduate Student Representative where she managed recruitment and served as a member of the admissions committee. Prior to graduate school, Amanda worked as a research assistant at Massachusetts General Hospital in the Division of Neurotherapeutics. Amanda graduated from Brown University with a Sc.B. in Neuroscience in 2009. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast, Professor Elliot Frohman discusses the treatment of acute optic neuritis and its connection with multiple sclerosis. Elliot Frohman is Professor of Neurology and Neurotherapeutics and Ophthalmology and Director of the Multiple Sclerosis and Neuroimmunology Program, at the University of Texas. Read the full paper here: http://jnnp.bmj.com/content/early/2014/10/29/jnnp-2014-308185.full

Episode #38 Running Time: 45:27 Podcast relevance: Professionals. Continuing education credit can be earned by listening to this episode. To learn more, please visit BehaviorTherapist.org In this episode R. Trent Codd, III, Ed.S. interviews Jan Mohlman, PhD about the Neurocognitive Perspective. Specifically, they discuss: What the neurocognitive perspective is and what it adds to traditional clinical work Challenging aspects of adding affective and cognitive neuroscience into clinical settings Emergent methodological and practice standards Patient perceptions of the approach How clinicians can pursue training in this perspective And more!   Jan Mohlman Biography Jan Mohlman, Ph.D. is Associate Professor at William Paterson University. Dr. Mohlman’s research seeks to explain how processes of aging (e.g., hearing loss, progressive brain disease, deficits in cognitive skills) impact the presentation and treatment of anxiety and other mood problems in later life.  Dr. Mohlman’s work also extends to treatment outcome research, applying methodology from affective and cognitive neuroscience to inform studies of cognitive behavior therapy.  Dr. Mohlman has published peer reviewed journal articles and book chapters and won several research grants, teaching and mentoring awards.    Coauthor Biographies Thilo Deckersbach, Ph.D. is Associate Professor of Psychology at Harvard Medical School. He serves as the Director of Psychology in the Bipolar Clinic and Research Program and as the Director of Research in the Division of Neurotherapeutics at the Massachusetts General Hospital in Boston. Dr. Deckersbach’s research has been supported by the National Institute of Mental Health, NARSAD, TSA, OCF, and DBDAT. He has published peer-reviewed papers and book chapters. His neuroimaging research (fMRI and PET) focuses on the interaction of cognitive and emotional processes in bipolar disorder.     Adam S. Weissman, Ph.D. is the Founder & Executive Director of Child & Family Cognitive Behavioral Psychology, PLLC in Scarsdale and Manhattan. Formerly Senior Clinical Consultant at Harvard Medical School, Dr. Weissman is currently on the Clinical Faculty at Columbia University, where he trains and supervises advanced doctoral students in CBT with children and adolescents. He is a nationally-recognized expert in the treatment of a wide range of youth anxiety and mood disorders, ADHD, disruptive behavior problems, tic/habit disorders, and related conditions, and has published peer-reviewed articles, book chapters, and edited books, the majority focusing on cognitive-behavioral therapy and neuropsychological assessment for children and adolescents.   Book Begin reading From Symptom to Synapse by clicking here.    Episode-related Links Personal Zen Neurocognitive Therapies/Translational Research Special Interest Group Association for Behavioral and Cognitive Therapies    

1) Small fiber neuropathy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steve Waxman about his paper on small fiber neuropathy. Dr. Jennifer Fugate is reading our e-Pearl of the week about diffusion-weighted imaging. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about other biomarkers for mild cognitive impairment and Alzheimer disease. Next week they will discuss preclinical Alzheimer disease. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Waxman serves on the editorial boards of Clinical Neuroscience, The Neurologist, Neurobiology of Disease, Clinical Neurology and Neurosurgery, SYNAPSE, Molecular Neurobiology, Clinical Neuroscience Research, Neuron-Glia Biology, Neurotherapeutics, Trends in Molecular Medicine, Molecular Pain and Channels; served on the editorial board Journal of Neurotrauma; serves on the scientific advisory board for Brain and Nature Reviews Neurology; Editor-in-Chief of The Neuroscientist and Neuroscience Letters; Editor of The Journal of Physiology; Section Head Multiple Sclerosis, Faculty of 1000 Medicine; is or has been a consultant for Cardiome Pharmaceutical, Bristol-Myers Squibb, Vertex Pharmaceutical, ChromaCell and DaiNippon Sumitomo Pharmaceuticals; receives research support from Pfizer Inc., The Erythromelalgia Association and Department of Veterans Affairs; holds stock options in SITE ONE Research for serving on its Advisory Board and is listed as an inventor for a patent held by Yale University on the Invention of sodium channel NaV1.9.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) 60th anniversary editorial and 2) Topic of the month: Preventive neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Robert Griggs about his editorial describing his tenure as Editor for the journal. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Lafora disease. In the next part of the podcast Dr. Matt Barrett interviews Dr. Renee Shellhaas about vitamin D deficiency in children with epilepsy. Next week Matt Barrett will interview Paula Rackoff about steroids and vitamin D, Calcium and osteoporosis. The participants had nothing to disclose except Drs. Burns, Griggs, Clardy, and Shellhaas.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Griggs serves as Chair of Executive Committee of the Muscle Study Group, which receives support from pharmaceutical companies; has served on scientific advisory boards for The National Hospital Queen Square and PTC Therapeutics, Inc.; serves on the editorial boards of NeuroTherapeutics and Current Treatment Opinions in Neurology; receives royalties from the publication of Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition (W.B. Saunders Company, 2000, 2004, 2007, and 2010) and Cecil Textbook of Medicine, 24th Edition (Saunders, 2000, 2004, 2008, and 2010, in press); and has received research support from TaroPharma and the NIH/NINDS, the FDA, and the Muscular Dystrophy Association.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Shellhaas receives research support from the NIH, University of Michigan through the Janette Ferrantino Investigator Award 2010 and Charles Woodson Pediatric Biostatics Fund Major Award 2011, and Child Neurology Foundation, Shields Fellowship Award 2009-2011.

Monday, June 6, 2011 – Our incredible special guest is Steven Hersch, MD, PhD, Professor of Neurology at Massachusetts General Hospital and Harvard Medical School; Director, Laboratory of Neurodegeneration and Neurotherapeutics, MassGeneral Institute for Neurodegeneration; Director, New England HDSA Center of Excellence for Huntington's Disease at MGH; Co-chair, Huntington Study Group; Principal Investigator of the CREST-E study; and Principal Investigator of the REVEAL-HD study.  “The central focus of my professional work is to care for families with Huntington's disease (HD) and to help develop treatments to slow or cure this fatal progressive neurogenetic disorder.”  Steven Hersch, MD, PhD

1) Voltage sensor mutations and 2) Topic of the month: Featured speakers from the AAN Meeting. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steve Cannon about his paper on voltage sensor mutations. In the next segment, Dr. Sarah Song is reading our e-Pearl of the week about Cogan's sign. In the next part of the podcast Dr. Alberto Espay interviews Dr. Robert Griggs about his Presidential Lecture. The LOTWs for the next three weeks of May will continue with more featured speakers from the AAN Meeting being interviewed. The participants had nothing to disclose except Drs. Burns, Cannon, Song, Espay and Griggs.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Cannon serves on the scientific advisory board for Telethon (Italy); serves on the editorial advisory board of the Journal of General Physiology; and receives research support from the NIH/NIAMS. Dr. Song served on the editorial team for the Neurology® Resident and Fellow Section. Dr. Espay serves on scientific advisory boards for Boehringer Ingelheim and Solvay Pharmaceuticals, Inc.; serves on the editorial advisory board for The European Neurological Journal; has received speaker honoraria from UCB/SCHWARZ PHARMA, Medtronic, Inc., and Novartis; has received honoraria from Novartis, the American Academy of Neurology, and the Movement Disorders Society; has served on speakers' bureaus for UCB/SCHWARZ PHARMA and Novartis; receives/has received research support from Medtronic, Inc., Allergan, Inc., CleveMed, the KL2 Research Scholars mentored career development award, and NIH Institutional Clinical and Translational Science Award (RR026315-02), Dean Scholar's Award - University of Cincinnati, Davis Phinney Foundation, and the Michael J Fox Foundation. Dr. Griggs serves as Chair of Executive Committee of the Muscle Study Group, which receives support from pharmaceutical companies; has served on scientific advisory boards for The National Hospital Queen Square and PTC Therapeutics, Inc.; serves on the editorial boards of NeuroTherapeutics and Current Treatment Opinions in Neurology; receives royalties from the publication of Andreoli and Carpenter's Cecil Essentials of Medicine, Eighth Edition (W.B. Saunders Company, 2000, 2004, 2007 and 2010) and Cecil Textbook of Medicine, 24th Edition (Saunders, 2000, 2004, 2008 and 2010 in press); has received research support from TaroPharma and the NIH (NINDS T32 NS07338 [PI and preceptor], 2 U54 NS059065-06 [PI], R01 NS045686-05 [PI], and NINDS 525326 [Co-PI]), the FDA, and from the Muscular Dystrophy Association.

An Interview with Andrew G. Engel, MD, author of The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007;4:252-257. Interviewed by Elliot Dimberg, MD and Jeremy Lanford, MD. The participants in this podcast had nothing to disclose.

An Interview with Andrew G. Engel, MD, author of The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007;4:252-257. Interviewed by Elliot Dimberg, MD and Jeremy Lanford, MD. The participants in this podcast had nothing to disclose.